Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies

The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Miriam, Caruso, Paola, Maiorino, Maria Ida, Bellastella, Giuseppe, Giugliano, Dario, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375203/
https://www.ncbi.nlm.nih.gov/pubmed/32698837
http://dx.doi.org/10.1186/s12933-020-01090-9
_version_ 1783561835042045952
author Longo, Miriam
Caruso, Paola
Maiorino, Maria Ida
Bellastella, Giuseppe
Giugliano, Dario
Esposito, Katherine
author_facet Longo, Miriam
Caruso, Paola
Maiorino, Maria Ida
Bellastella, Giuseppe
Giugliano, Dario
Esposito, Katherine
author_sort Longo, Miriam
collection PubMed
description The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.
format Online
Article
Text
id pubmed-7375203
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73752032020-07-23 Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies Longo, Miriam Caruso, Paola Maiorino, Maria Ida Bellastella, Giuseppe Giugliano, Dario Esposito, Katherine Cardiovasc Diabetol Commentary The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients. BioMed Central 2020-07-22 /pmc/articles/PMC7375203/ /pubmed/32698837 http://dx.doi.org/10.1186/s12933-020-01090-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Longo, Miriam
Caruso, Paola
Maiorino, Maria Ida
Bellastella, Giuseppe
Giugliano, Dario
Esposito, Katherine
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
title Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
title_full Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
title_fullStr Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
title_full_unstemmed Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
title_short Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
title_sort treating type 2 diabetes in covid-19 patients: the potential benefits of injective therapies
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375203/
https://www.ncbi.nlm.nih.gov/pubmed/32698837
http://dx.doi.org/10.1186/s12933-020-01090-9
work_keys_str_mv AT longomiriam treatingtype2diabetesincovid19patientsthepotentialbenefitsofinjectivetherapies
AT carusopaola treatingtype2diabetesincovid19patientsthepotentialbenefitsofinjectivetherapies
AT maiorinomariaida treatingtype2diabetesincovid19patientsthepotentialbenefitsofinjectivetherapies
AT bellastellagiuseppe treatingtype2diabetesincovid19patientsthepotentialbenefitsofinjectivetherapies
AT giuglianodario treatingtype2diabetesincovid19patientsthepotentialbenefitsofinjectivetherapies
AT espositokatherine treatingtype2diabetesincovid19patientsthepotentialbenefitsofinjectivetherapies

Ejemplares similares